Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Artiva Biotherapeutics has raised $300.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Artiva Biotherapeutics's investors include Franklin Templeton, RA Capital Management, Blackstone Credit, Cormorant Asset Management, Janus Henderson Investors.
Artiva Biotherapeutics is headquartered in San Diego, United States.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Artiva Biotherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Artiva Biotherapeutics — Funding & Investors." VCBacked, May 8, 2026, https://www.vcbacked.co/company/artiva-biotherapeutics. Accessed October 30, 2026.
VCBacked. (2026). Artiva Biotherapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/artiva-biotherapeutics
{{cite web |title=Artiva Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/artiva-biotherapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated